全文获取类型
收费全文 | 2346篇 |
免费 | 135篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 31篇 |
妇产科学 | 13篇 |
基础医学 | 315篇 |
口腔科学 | 75篇 |
临床医学 | 99篇 |
内科学 | 734篇 |
皮肤病学 | 20篇 |
神经病学 | 183篇 |
特种医学 | 73篇 |
外科学 | 461篇 |
综合类 | 12篇 |
预防医学 | 98篇 |
眼科学 | 24篇 |
药学 | 119篇 |
中国医学 | 9篇 |
肿瘤学 | 223篇 |
出版年
2024年 | 1篇 |
2023年 | 18篇 |
2022年 | 25篇 |
2021年 | 57篇 |
2020年 | 24篇 |
2019年 | 38篇 |
2018年 | 51篇 |
2017年 | 44篇 |
2016年 | 55篇 |
2015年 | 47篇 |
2014年 | 59篇 |
2013年 | 102篇 |
2012年 | 142篇 |
2011年 | 169篇 |
2010年 | 99篇 |
2009年 | 84篇 |
2008年 | 141篇 |
2007年 | 174篇 |
2006年 | 151篇 |
2005年 | 183篇 |
2004年 | 162篇 |
2003年 | 160篇 |
2002年 | 164篇 |
2001年 | 38篇 |
2000年 | 32篇 |
1999年 | 29篇 |
1998年 | 31篇 |
1997年 | 33篇 |
1996年 | 19篇 |
1995年 | 17篇 |
1994年 | 13篇 |
1993年 | 17篇 |
1992年 | 15篇 |
1991年 | 21篇 |
1990年 | 23篇 |
1989年 | 14篇 |
1988年 | 11篇 |
1987年 | 13篇 |
1986年 | 6篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1975年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有2503条查询结果,搜索用时 21 毫秒
91.
Nagata Kosei Oshima Yasushi Nakamoto Hideki Sakamoto Ryuji Ohtomo Nozomu Izuka Masaaki Nakajima Koji Yoshimoto Takahiko Fujii Tomoko Matsudaira Ko Tanaka Sakae Oka Hiroyuki 《European spine journal》2020,29(6):1435-1444
European Spine Journal - To investigate the psychometric properties of the Japanese version of the Core Outcome Measures Index-Back (COMI-Back), only recently published according to the established... 相似文献
92.
Joseph F. Bower Jennifer B. McClung Carl Watson Takahiko Osumi Kátia Pastre 《The AAPS journal》2014,16(2):352-356
The continued globalization of pharmaceutics has increased the demand for companies to know and understand the regulations that exist across the globe. One hurdle facing pharmaceutical and biotechnology companies developing new drug candidates is interpreting the current regulatory guidance documents and industry publications associated with bioanalytical method validation (BMV) from each of the different agencies throughout the world. The objective of this commentary is to provide our opinions on the best practices for reference standards and key reagents, such as metabolites and internal standards used in the support of regulated bioanalysis based on a review of current regulatory guidance documents and industry white papers for BMV. 相似文献
93.
Miguel A. Lanaspa Takuji Ishimoto Christina Cicerchi Yoshifuru Tamura Carlos A. Roncal-Jimenez Wei Chen Katsuyuki Tanabe Ana Andres-Hernando David J. Orlicky Esteban Finol Shinichiro Inaba Nanxing Li Christopher J. Rivard Tomoki Kosugi Laura G. Sanchez-Lozada J. Mark Petrash Yuri Y. Sautin A. Ahsan Ejaz Wataru Kitagawa Gabriela E. Garcia David T. Bonthron Aruna Asipu Christine P. Diggle Bernardo Rodriguez-Iturbe Takahiko Nakagawa Richard J. Johnson 《Journal of the American Society of Nephrology : JASN》2014,25(11):2526-2538
Diabetes is associated with activation of the polyol pathway, in which glucose is converted to sorbitol by aldose reductase. Previous studies focused on the role of sorbitol in mediating diabetic complications. However, in the proximal tubule, sorbitol can be converted to fructose, which is then metabolized largely by fructokinase, also known as ketohexokinase, leading to ATP depletion, proinflammatory cytokine expression, and oxidative stress. We and others recently identified a potential deleterious role of dietary fructose in the generation of tubulointerstitial injury and the acceleration of CKD. In this study, we investigated the potential role of endogenous fructose production, as opposed to dietary fructose, and its metabolism through fructokinase in the development of diabetic nephropathy. Wild-type mice with streptozotocin-induced diabetes developed proteinuria, reduced GFR, and renal glomerular and proximal tubular injury. Increased renal expression of aldose reductase; elevated levels of renal sorbitol, fructose, and uric acid; and low levels of ATP confirmed activation of the fructokinase pathway. Furthermore, renal expression of inflammatory cytokines with macrophage infiltration was prominent. In contrast, diabetic fructokinase–deficient mice demonstrated significantly less proteinuria, renal dysfunction, renal injury, and inflammation. These studies identify fructokinase as a novel mediator of diabetic nephropathy and document a novel role for endogenous fructose production, or fructoneogenesis, in driving renal disease.Diabetic nephropathy is the most common kidney disease causing ESRD worldwide and also one of the most difficult diseases to treat. To date, treatment includes tight blood glucose and BP control and inhibition of the renin-angiotensin-aldosterone system. These efforts typically slow but do not arrest the progression of kidney disease.1 It is therefore imperative to better understand the mechanisms responsible for renal injury and to develop additional therapies.Recently, fructose has emerged as a potential nephrotoxin. Fructose-fed rats develop modest tubulointerstitial injury,2 and fructose supplementation accelerates renal disease in the remnant kidney model.3 While all studies to date have focused on dietary fructose as the source of fructose, fructose can also be generated from glucose in diabetes because of the activation of the polyol pathway in the proximal tubule. To date, no studies have examined the role of this endogenous fructose production or fructoneogenesis in driving diabetic nephropathy. Therefore, we tested the hypothesis that mice lacking fructokinase-ketohexokinase (khk−/−) show protection from diabetic nephropathy, even in the absence of dietary fructose, as a result of their inability to metabolize endogenously produced fructose. 相似文献
94.
95.
96.
Yukiko Saitou Katsuya Shiraki Takenari Yamanaka Kazumi Miyashita Tomoko Inoue Yutaka Yamanaka Yumi Yamaguchi Naoyuki Enokimura Norihiko Yamamoto Keiichi Itou Kazushi Sugimoto Takeshi Nakano 《World journal of gastroenterology : WJG》2005,11(40)
AIM: To investigate the reduction of cell viability in human hepatocellular carcinoma (HCC) cell lines induced by inhibition of nuclear factor κB (NFκB).METHODS: HLE, SKHep1, and HepG2 were incubated and E3330 was used to compare the stimulation of some chemotherapeutic drugs with that of TNF family, Fas ligand, TNFα and TNF-related apoptosis-inducing ligand (TRAIL) at the point of the reduction of cell viability by inhibiting NFκB.RESULTS: E3330 decreased NFκB levels in HLE cells stimulated by TNF and TRAIL. The cytotoxicity of the combination of TRAIL, TNFα, Fas ligand, and E3330increased synergistically in a dose-dependent manner compared to either E3330 alone in all HCC cell lines by MTT assay. However, the combination of some chemotherapeutic drugs and E3330 did not decrease the cell viability.CONCLUSION: Inhibition of NFκB sensitizes human HCC cell lines to TNF-mediated apoptosis including TRAIL, and TRAIL-based tumor therapy might be a powerful potential therapeutic tool in the treatment of human HCC. 相似文献
97.
Oolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery disease 总被引:4,自引:0,他引:4
Shimada K Kawarabayashi T Tanaka A Fukuda D Nakamura Y Yoshiyama M Takeuchi K Sawaki T Hosoda K Yoshikawa J 《Diabetes research and clinical practice》2004,65(3):227-234
BACKGROUND: Oolong tea has been studied for its effect on cardiovascular disease and obesity. Plasma adiponectin levels are reduced in obesity, in patients with type 2 diabetes mellitus and in coronary artery disease (CAD). OBJECTIVE: To investigate prospectively, whether intake of Oolong tea influences plasma adiponectin levels, low-density lipoprotein (LDL) particle size, total cholesterol, high-density lipoprotein (HDL) cholesterol, LDL cholesterol, serum triglyceride and plasma glucose levels in patients with CAD. METHODS: Twenty two patients in our study consumed Oolong tea (1000 ml) or water for 1 month in our randomized cross-over study design. RESULTS: There was a significant difference in plasma adiponectin levels before and after 1 month intake of Oolong tea (6.26 +/- 3.26 microg/ml versus 6.88 +/- 3.28 microg/ml, P < 0.05), and in plasma level LDL particle size (25.02+/-0.67 nm versus 25.31+/-0.60 nm, P < 0.01). The water-consuming control group showed no changes (6.28+/-3.28 microg/ml versus 6.23+/-3.21 microg/ml) in adiponectin levels or LDL particle sizes (25.03+/-0.70 nm versus 25.02+/-0.72 nm). We also observed a significant difference in hemoglobin A1c levels (7.23 +/- 4.45% versus 6.99 +/- 4.30%, P < 0.05) before and after intake of Oolong tea. CONCLUSION: Oolong tea may have beneficial effects on the progression of atherosclerosis in patients with CAD. 相似文献
98.
99.
MPO-ANCA-positive Wegener’s granulomatosis presenting with hypertrophic cranial pachymeningitis: case report and review of the literature 总被引:1,自引:1,他引:1
Akahoshi M Yoshimoto G Nakashima H Miyake K Inoue Y Tanaka Y Tsukamoto H Horiuchi T Otsuka T Harada M 《Modern rheumatology / the Japan Rheumatism Association》2004,14(2):179-183
We describe a case of hypertrophic cranial pachymeningitis (HCP) associated with Wegeners granulomatosis (WG) in a 60-year-old man presenting with chronic headache and multiple cranial nerve neuropathies. A test for antibodies to the neutrophil cytoplasmic protein myeloperoxidase (MPO-ANCA) was positive in this case. We review the literature on perinuclear (p)-ANCA-related HCP, including our case. This case indicates the link between MPO-ANCA-positive WG and HCP. 相似文献
100.
Hisato Nakazawa Masataka Komori Yuta Shibamoto Takahiko Tsugawa Yoshimasa Mori Tatsuya Kobayashi 《Acta neurochirurgica》2014,156(8):1483-1489